Evidence map›Paper›PMID 29164804›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2018

Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

DaShawn A Hickman, Christa L Pawlowski, Ujjal D S Sekhon, Joyann Marks, Anirban Sen Gupta

Open access · greenAbstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 544 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

DaShawn A HickmanDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Christa L PawlowskiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Ujjal D S SekhonDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Joyann MarksDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Anirban Sen GuptaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Case Western Reserve University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet AnaloguesR01HL121212 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SEN GUPTA, ANIRBAN · 2014 to 2024
$4.1M
NRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9M
Clinical and Translational Science Collaborative of ClevelandTL1TR000441 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$2.8M
NCATS NIH HHS TL1 TR002549NHLBI NIH HHS R01 HL121212NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Bleeding complications arising from trauma, surgery, and as congenital, disease-associated, or drug-induced blood disorders can cause significant morbidities and mortalities in civilian and military populations. Therefore, stoppage of bleeding (hemostasis) is of paramount clinical significance in prophylactic, surgical, and emergency scenarios. For externally accessible injuries, a variety of natural and synthetic biomaterials have undergone robust research, leading to hemostatic technologies including glues, bandages, tamponades, tourniquets, dressings, and procoagulant powders. In contrast, treatment of internal noncompressible hemorrhage still heavily depends on transfusion of whole blood or blood's hemostatic components (platelets, fibrinogen, and coagulation factors). Transfusion of platelets poses significant challenges of limited availability, high cost, contamination risks, short shelf-life, low portability, performance variability, and immunological side effects, while use of fibrinogen or coagulation factors provides only partial mechanisms for hemostasis. With such considerations, significant interdisciplinary research endeavors have been focused on developing materials and technologies that can be manufactured conveniently, sterilized to minimize contamination and enhance shelf-life, and administered intravenously to mimic, leverage, and amplify physiological hemostatic mechanisms. Here, a comprehensive review regarding the various topical, intracavitary, and intravenous hemostatic technologies in terms of materials, mechanisms, and state-of-art is provided, and challenges and opportunities to help advancement of the field are discussed.

Indexed as

BandagesBiocompatible MaterialsHemorrhageHemostasisHemostaticsHumansBiocompatible MaterialsHemostaticsbiomaterialshemostasisplateletstransfusionwound dressings

Identifiers

PMID29164804
PMCPMC5831165
OpenAlexW2770162756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.